Study shows that high-dose, high-frequency interferon produces no addition... ( CAMBRIDGE MA April 15 2008 -- Resul...)

Study shows that high-dose, high-frequency interferon produces no additional benefit

Date:4/15/2008

CAMBRIDGE, MA April 15, 2008 -- Results of a phase IV, open label, head-to-head study of intramuscular AVONEX and high-dose, high-frequency subcutaneous Rebif (interferon beta-1a) provide clinical evidence that the two drugs show similar efficacy over 18 to 30 months of continued therapy in patients with relapsing-remitting multiple sclerosis (RRMS). These data are published in the April 2008 issue of the Current Medical Research and Opinion journal.

The Prospective and Retrospective Long-Term Observational Study of AVONEX and Rebif (PROOF), involved 217 patients with 136 completing a median of 25.9 months of AVONEX 30 mcg once weekly (n=69) and a median of 22.2 months Rebif 44 mcg three times weekly (n=67).

Led by a group of principal investigators including Dr. T. Jock Murray of Division of Neurology, Dalhousie MS Research Unit, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia; Canada; and Dr. Alireza Minagar, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana, the study provides further clinical evidence that the dose and frequency of treatment shows no advantage on delivering better efficacy.

Upon evaluation of baseline disability, Expanded Disability Status Scale (EDSS) scores showed no statistically significant differences between the two treatment groups during the prospective portion of the study, with sustained disability progression similar for both: 25.8 percent for AVONEX vs. 26.7 percent for Rebif. Additional key findings include:

Relapse rates, MRI endpoints of brain parenchymal fraction, T1 lesion volume, T2 lesion volume, number of new/enlarging T2 lesions and gadolinium enhancing (Gd+) lesion volume and count were also comparable between both groups.
In addition, 19 percent of patients taking Rebif tested positive for neutralizing antibodies (NAbs) at end of treatment compared with zero percent taking AVONEX.

Given th
'/>"/>

Contact: Kathleen Vigneault
kathleen.vigneault@mslpr.com
Manning Selvage & Lee
Source:Eurekalert

0

GOOD

Page: 1 2
Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks

Post Your Comments:

(Date:12/6/2009)..., Hamilton, ON. Dec. 6, 2009 A new study provide... disorder known as venous thromboembolism (VTE). ...nadians and half-a-million Americans every year, a...d restricts the flow of blood, causing pain and sw...s point of origin and travel through the heart to ...

(Date:12/6/2009)..., Attorney Joseph W. Bell...ances such as asbestos have been found in toys in ...ew York, NY (PRWEB) December 6, 2009 -- As parents...n, they should be alert to reports of recalls due ...w York personal injury lawyer., , ,“Close to...

(Date:12/5/2009)WASHINGTON, Dec. 5 ,, What: Cuts for a Cause ,, Why: To make a difference in the fight against cancer and other terminal illnesses affecting children. All proceeds from each hair service given

(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int

(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for

[0] New drug shows promise for those with clotting disorders: McMaster researcher [0] Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season [0] Salon Leau to Host 'Cuts for a Cause' to Raise Funds and Spread the Word About Childhood Terminal Illnesses [0] Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders [0] Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification

... California,s San Antonio,Community Hospital in Up...ll(R) Gamma Knife Perfexion(TM). A revolutionary a...aily radiation treatments, Leksell,Gamma Knife Per...tumors and other brain disorders., Developed in c...

...for stress-free summer travel, designed for ...Calif., June 3 Pharmacopia,s Aromatherapy,Luxurie... nerves during,flight delays and long waits in air...t back on plastic., No need to dry out your skin ...

...s Fill Important Medical Niche for Customers, FOR...ader in the ergonomic sleep and body comfort indus...lth care market as more national drug stores,are o...reating more paperwork and longer lag times, drug ...

... mutations that lead to disease, study concludes ,...erson,s risk of cancer increases if he or she suff...intestine or stomach, such as ulcerative colitis, ...lished in the June 2 online issue of the Journal ...

... Cancer is the Number One Cause of Death in...eking to Treat and Cure Dogs, DENVER, June 3 Mor...site, http://www.MorrisAnimalFoundation.org, a c...death in dogs over the age of two. The MAF canine ...

...swire-FirstCall/ - Nuvo Research Inc.,(TSX: NRI), ... research and,development of drug products deliver...ransdermal drug delivery technologies, and Paladin...ennsaid(R) (topical diclofenac). Paladin sells and...

Other Medicine News:Health News:San Antonio Community Hospital Commissions Leksell Gamma Knife(R) Perfexion(TM) To Serve Over 3 Million Californians 2 Health News:Aromatherapy Luxuries for the Eco-Friendly Traveler 2 Health News:Contour Products(TM) Works with National Drug Store Chains to Offer 'Cash-and-Carry' Ergonomic Sleep and Body Comfort Items 2 Health News:Chronic Stomach Inflammation Boosts Cancer Risk 2 Health News:Canine Cancer Web Exclusive for Dog Owners and Lovers, Presented by Morris Animal Foundation - Features Colorado State and Cornell University Veterinary Cancer Experts 2 Health News:New Improved Dosing Approved for Pennsaid 2

San Antonio Community Hospital Commissions Leksell Gamma Knife(R) Perfexion(TM) To Serve Over 3 Million Californians Aromatherapy Luxuries for the Eco-Friendly Traveler Contour Products(TM) Works with National Drug Store Chains to Offer 'Cash-and-Carry' Ergonomic Sleep and Body Comfort Items Chronic Stomach Inflammation Boosts Cancer Risk Canine Cancer Web Exclusive for Dog Owners and Lovers, Presented by Morris Animal Foundation - Features Colorado State and Cornell University Veterinary Cancer Experts New Improved Dosing Approved for Pennsaid

(Date:12/4/2009)SAN DIEGO, Calif., Dec. 4 Suneva Medical, a privately-held aesthetic medical device company, today announced the appointment of Philip Ranker as Vice President and Chief Financial Officer. In this r

(Date:12/4/2009)MORRISTOWN, N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed

(Date:12/4/2009)BETHESDA, Md., Dec. 4 Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC Bulletin Board: NWBO) announced today that the US Patent and Trademark Office has allowed its patent application o

Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2 Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3 Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4 Watson Files FDA Application for Generic Rozerem(R) 2 Watson Files FDA Application for Generic Rozerem(R) 3 Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2 Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3 Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4 Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5 AUDIO from Medialink and Majestic Drug Company 3A When the Tooth Hurts 60261 1 Just Released New Poll 3A Healthcare Through Womens Eyes 60259 1 Just Released New Poll 3A Healthcare Through Womens Eyes 60259 2 Shu Tung Li Founder and CEO of Collagen Matrix Inc Honored as 2009 New Jersey Executive of the Year Finalist and Company Named One of Fifty Fastest 60257 1 Shu Tung Li Founder and CEO of Collagen Matrix Inc Honored as 2009 New Jersey Executive of the Year Finalist and Company Named One of Fifty Fastest 60257 2

[0] Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer [0] Watson Files FDA Application for Generic Rozerem(R)[0] Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing

MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis

Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee

Other Medicine Technology:MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2 MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3 MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4 MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5 Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2 Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3

MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee

Black Multi-Pinhole Occluder

Long Handle Occluder - Black

60mm Lens Blank

Translucent White-Long

Medicine Products:

Black Multi-Pinhole Occluder Long Handle Occluder - Black 60mm Lens Blank Translucent White-Long

Study shows that high-dose, high-frequency interferon produces no addition...( CAMBRIDGE MA April 15 2008 -- Resul...),Health